SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-256260
Filing Date
2022-10-03
Accepted
2022-10-03 09:18:01
Documents
14
Period of Report
2022-10-03
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d403551d8k.htm   iXBRL 8-K 25312
2 EX-99.1 d403551dex991.htm EX-99.1 26846
6 GRAPHIC g403551g1002230918792.jpg GRAPHIC 3070
  Complete submission text file 0001193125-22-256260.txt   187365

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA lgnd-20221003.xsd EX-101.SCH 2854
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE lgnd-20221003_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lgnd-20221003_pre.xml EX-101.PRE 11260
8 EXTRACTED XBRL INSTANCE DOCUMENT d403551d8k_htm.xml XML 3415
Mailing Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121
Business Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121 858-550-7500
LIGAND PHARMACEUTICALS INC (Filer) CIK: 0000886163 (see all company filings)

IRS No.: 770160744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33093 | Film No.: 221286225
SIC: 2834 Pharmaceutical Preparations